If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting As filed with the Securities and Exchange Commission on January 26, 2026 Washington, D.C. 20549 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Akanda Corp. c/o Gowling WLG (Canada) LLP 100 King St. W, Suite 1600 Toronto, ON M5X 1G5, Canada Tel: +1 (4 ...

As filed with the Securities and Exchange Commission on September 16, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Universal Safety Products, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Maryland 5065 52-0898545 (I.R.S. Employer Identification No.) 11407 Cro ...

Core Viewpoint - Akanda Corp. has announced a $12.0 million convertible note offering to institutional investors, which will be utilized for various corporate purposes [1][2]. Group 1: Financial Details - The offering consists of 12-month convertible promissory notes with an aggregate purchase price of up to $12.0 million [1]. - Proceeds from the sale will be allocated as follows: up to $3.5 million for marketing, continued development of the Gabriola, B.C. site, up to $3 million for working capital and general corporate purposes, and up to $7 million for debt repayment [2]. Group 2: Transaction Agents - Univest Securities, LLC served as the exclusive placement agent for the offering [3]. - Legal counsel for the transaction included Ruskin Moscou Faltischek PC for the Company and Sullivan & Worcester LLP for the placement agent, with Gowling WLG (Canada) LLP acting as Canadian counsel [3]. Group 3: Regulatory Information - The notes and common shares from the conversion have not been registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an exemption [4]. - Additional details regarding the notes and the transaction will be available in the Company's Form 6-K, which will be filed with the U.S. Securities and Exchange Commission [5].

Core Points - Indaptus Therapeutics, Inc. has raised a total of $5.7 million through the sale of convertible promissory notes and accompanying warrants [1][2] - The notes have a 6% annual interest rate and will mature on July 28, 2026, with conversion into common stock at a price equal to 80% of the average Nasdaq closing price for the five trading days prior to conversion, capped at $11.20 [2] - Warrants to purchase 200% of the conversion shares will be issued upon conversion, with an exercise price equal to the conversion price and a term of five years [3] - The net proceeds from the offering will be used for research and development activities, including funding a Phase 1b/2 clinical trial, as well as for working capital and general corporate purposes [4]

As filed with the Securities and Exchange Commission on October 12, 2023. REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sadot Group Inc. (Exact Name of Registrant as Specified in its Charter) incorporation or organization Classification Code Number) Identification Number) Registration No. 333-______ Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM S-1 Nevada 5810 47-2555533 State or other jurisdiction (Primary Standard Industrial (I.R.S. Employer 1751 River Run, Suite 2 ...